Abstract
Bronchial asthma is one of the most common chronic diseases that in most cases responds well to treatment. In about 5% of patients, however, despite the best efforts of both the patient and the physician, achieving asthma control is problematic.
As recommended by the Global Asthma Initiative, patients whose asthma is not adequately controlled through treatment with high-dose inhaled corticosteroids in combination with long-acting β2-agonists (LABAs), biological therapy should be preferred over long-term systemic corticotherapy. In patients with severe eosinophilic asthma - i.e. those with severe eosinophilic airway inflammation usually associated with an increased number of eosinophils in the blood - we have the option of indicating therapy aimed at influencing the interleukin 5 (IL-5) signaling pathway, IgE therapy or the biologics-blocking effect of interleukin 4 (IL-4) and interleukin 13 (IL-13).
However, the selection of potential responders to the biological treatment of asthma in general and from the perspective of individual biologists remains relatively complicated.